Kabalak PA, Kızılgöz D, Yılmaz U, et al. - Given curative approaches focused on both the primary tumour and metastasis afford higher survival rates even in oligometastatic stage 4 disease, therefore, researchers performed a retrospective study of their outcomes of oligometastatic disease. They examined data for 52 non-small-cell lung cancer (NSCLC) patients with limited metastasis (one to three synchronous/metachronous). The median overall survival (OS) time was estimated to be 35.2 ± 4.1 mo. For OS, surgery was found superior to chemoradiotherapy. Progression-free survival was estimated to be 29.4 ± 3.9 mo, and survival after first progression (SAFP) was estimated to be 15.6 ± 2.8 mo. Better SAFP related to an adenocarcinoma vs a non-adenocarcinoma was evident. The 1- and 2-y OS rates were estimated to be 67% and 50.4%, respectively. In the curative treatment group, an OS of 31 mo and 22 mo was reported for patients younger than 65 y (n = 25) and those older than 65 y (n = 13), respectively. Findings revealed that survival rates can reach up to 3 y even in geriatric people among well-selected NSCLC patients with limited metastasis. Essential prognostic factors were clinical N staging and co-morbidity.